Literature DB >> 24188160

The role of tumor progression locus 2 protein kinase in glial inflammatory response.

Joshua Hirschhorn1, Sangeeta Mohanty, Narayan R Bhat.   

Abstract

Tumor progression locus 2 (Tpl2)/cancer Osaka thyroid kinase is a newer member of MAP3K family that is now known for its essential role in tumor necrosis factor-aplha (TNFα) expression in macrophages, but its pro-inflammatory signaling, if any, in glia is unknown. When cultures of murine microglia and astrocytes were exposed to lipopolysaccharide, there was a rapid activation (i.e., phosphorylation) of Tpl2 in parallel to the activation of down-stream effector MAPKs, that is, extracellular signal regulated kinase (ERK), p38 MAPK and C-Jun N-terminal kinase (JNK). Pre-incubation of the cultures with a Tpl2 inhibitor selectively suppressed the activation of the primary down-stream target, that is, ERK relative to p38 MAPK and JNK. That Tpl2 activation was functionally involved in glial inflammatory response was indicated by a reduced release of the cytokines, i.e. TNFα and the expression of inducible nitric oxide synthase in the presence of the kinase inhibitor. Furthermore, over-expression of a wild-type Tpl2 construct in C-6 glia resulted in an enhanced transcriptional activation of inducible nitric oxide synthase, while transfection with a dominant negative form of Tpl-2 had the opposite effect. The findings assign an important pro-inflammatory signaling function for Tpl2 pathway in glial cells.
© 2013 International Society for Neurochemistry.

Entities:  

Keywords:  MAP kinase; astrocytes; cytokines; microglia; neuroinflammation; nitric oxide

Mesh:

Substances:

Year:  2013        PMID: 24188160      PMCID: PMC3951670          DOI: 10.1111/jnc.12522

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

1.  Cot/tpl2 (MAP3K8) mediates myeloperoxidase activity and hypernociception following peripheral inflammation.

Authors:  Irene Soria-Castro; Agnieszka Krzyzanowska; Marta López Pelaéz; Javier Regadera; Gema Ferrer; Lluis Montoliu; Rosario Rodríguez-Ramos; Margarita Fernández; Susana Alemany
Journal:  J Biol Chem       Date:  2010-08-24       Impact factor: 5.157

Review 2.  Tpl2 kinase signal transduction in inflammation and cancer.

Authors:  Maria Vougioukalaki; Dimitris C Kanellis; Kalliopi Gkouskou; Aristides G Eliopoulos
Journal:  Cancer Lett       Date:  2011-03-05       Impact factor: 8.679

3.  Cot/tpl2 activity is required for TLR-induced activation of the Akt p70 S6k pathway in macrophages: Implications for NO synthase 2 expression.

Authors:  Marta López-Peláez; Irene Soria-Castro; Lisardo Boscá; Margarita Fernández; Susana Alemany
Journal:  Eur J Immunol       Date:  2011-05-24       Impact factor: 5.532

4.  Inhibition of tumor progression locus 2 protein kinase decreases lipopolysaccharide-induced tumor necrosis factor alpha production due to the inhibition of the tip-associated protein induction in RAW264.7 cells.

Authors:  Kazuya Hirata; Masahiko Miyashiro; Hirofumi Ogawa; Hirofumi Taki; Kazuyuki Tobe; Takahisa Sugita
Journal:  Biol Pharm Bull       Date:  2010       Impact factor: 2.233

5.  TNF-alpha induction by LPS is regulated posttranscriptionally via a Tpl2/ERK-dependent pathway.

Authors:  C D Dumitru; J D Ceci; C Tsatsanis; D Kontoyiannis; K Stamatakis; J H Lin; C Patriotis; N A Jenkins; N G Copeland; G Kollias; P N Tsichlis
Journal:  Cell       Date:  2000-12-22       Impact factor: 41.582

6.  The Tpl2 mutation Sluggish impairs type I IFN production and increases susceptibility to group B streptococcal disease.

Authors:  Nengming Xiao; Celine Eidenschenk; Philippe Krebs; Katharina Brandl; Amanda L Blasius; Yu Xia; Kevin Khovananth; Nora G Smart; Bruce Beutler
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

Review 7.  Cot/Tpl-2 protein kinase as a target for the treatment of inflammatory disease.

Authors:  D George; A Salmeron
Journal:  Curr Top Med Chem       Date:  2009       Impact factor: 3.295

8.  Cot/tpl2-MKK1/2-Erk1/2 controls mTORC1-mediated mRNA translation in Toll-like receptor-activated macrophages.

Authors:  Marta López-Pelaéz; Stefano Fumagalli; Carlos Sanz; Clara Herrero; Susana Guerra; Margarita Fernandez; Susana Alemany
Journal:  Mol Biol Cell       Date:  2012-06-06       Impact factor: 4.138

9.  Tumor progression locus 2/Cot is required for activation of extracellular regulated kinase in liver injury and toll-like receptor-induced TIMP-1 gene transcription in hepatic stellate cells in mice.

Authors:  Maria J Perugorria; Lindsay B Murphy; Nicola Fullard; Jayashree B Chakraborty; Dimitra Vyrla; Caroline L Wilson; Fiona Oakley; Jelena Mann; Derek A Mann
Journal:  Hepatology       Date:  2013-03       Impact factor: 17.425

10.  The protein kinase TPL2 is essential for ERK1/ERK2 activation and cytokine gene expression in airway epithelial cells exposed to pathogen-associated molecular patterns (PAMPs).

Authors:  Guy Martel; Julie Bérubé; Simon Rousseau
Journal:  PLoS One       Date:  2013-03-19       Impact factor: 3.240

View more
  3 in total

1.  Postnatal activation of TLR4 in astrocytes promotes excitatory synaptogenesis in hippocampal neurons.

Authors:  Yi Shen; Huaping Qin; Juan Chen; Lingyan Mou; Yang He; Yixiu Yan; Hang Zhou; Ya Lv; Zhong Chen; Junlu Wang; Yu-Dong Zhou
Journal:  J Cell Biol       Date:  2016-11-10       Impact factor: 10.539

2.  Prognostic role of TPL2 in early‑stage non‑small cell lung cancer.

Authors:  Laura Boldrini; Mirella Giordano; Adele Servadio; Cristina Niccoli; Pietro Bertoglio; Marco Lucchi; Franca Melfi; Alfredo Mussi; Gabriella Fontanini
Journal:  Mol Med Rep       Date:  2017-04-03       Impact factor: 2.952

3.  Inhibition of the MAP3 kinase Tpl2 protects rodent and human β-cells from apoptosis and dysfunction induced by cytokines and enhances anti-inflammatory actions of exendin-4.

Authors:  E M Varin; A Wojtusciszyn; C Broca; D Muller; M A Ravier; F Ceppo; E Renard; J-F Tanti; S Dalle
Journal:  Cell Death Dis       Date:  2016-01-21       Impact factor: 8.469

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.